1998

• Founded by Bernard Mach, a former professor and director of the Department of Genetics and Microbiology, Faculty of Medicine, University of Geneva, and a specialist in the molecular biology of immune response genes and the inventor of cDNA cloning.

2000

• First Round of Financing CHF 15 million, Lead Investors LODH Immunology Fund, Novartis Venture Fund
• Hire of Jack Barbut, CEO

2002

• Hire of Marie Kosco-Vilbois, CSO

2005

• Corporate transaction with Serono, (Product License deal)
• Series B Financing round CHF 14 million

2006

• Series B Financing round CHF 58 M led by BZ Bank
• First in Men with NI-0401

2007

•  NovImmune moves to the new facility in Plan-les-Ouates

2008

• Ed Holdener becomes Chairman of the Board of Directors of NovImmune
• NI-0401:
  
  • Completion of PIIa in allograft renal transplantation
  • Completion of PI/IIa in Crohn's Disease
  • Initiation of PII in Crohn's Disease
• First in Men with NI-0801
• Hiring of Luca Bolliger, Director BD

2009

• Hiring of Olivia Maurel, Director Regulatory
• NI reacquires NI-0401 and NI-0501 rights back from MerckSerono
• Financing round CHF 62.5 M led by BZ Bank
• Hiring of Karim Abdelatif, Director HR
• Winner of the European Biotechnica Award

2010

• Hiring of Cristina De Min, CMO